Advertisement

Topics

Latest "Advanced Research Systems, Inc." News Stories - Page: 2

10:16 EDT 19th October 2018 | BioPortfolio

Here are the most relevant search results for "Advanced Research Systems, Inc." found in our extensive news archives from over 250 global news sources.

More Information about Advanced Research Systems, Inc. on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Advanced Research Systems, Inc. for you to read. Along with our medical data and news we also list Advanced Research Systems, Inc. Clinical Trials, which are updated daily. BioPortfolio also has a large database of Advanced Research Systems, Inc. Companies for you to search.

Showing "Advanced Research Systems" News Articles 26–50 of 35,000+

Friday 19th October 2018

TP Therapeutics Completes $80 Million Mezzanine Financing Co-Led by Foresite Capital and venBio Partners

Dr. Athena Countouriotis Promoted to Chief Executive Officer and Member of the Board of Directors Dr. Peter Li Named Head of TP Therapeutics Asia TP Therapeutics, a clinical-stage precision oncology company developing novel drugs that address treatment resistance, today announced its completion of an $80 million round of mezzanine fi...


Glenmark Pharmaceuticals Inc Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 27092018] Prices from USD $250

SummaryGlenmark Pharmaceuticals Inc USA Glenmark Pharmaceuticals, formerly Glenmark Generics Inc USA, a subsidiary of Glenmark Pharmaceuticals Ltd, is a manufacturer of generic pharmaceutical products. The company's products include acamprosate calcium delayed release tablets, adapalene gel, alclometasone dipropionate cream, alclometasone dipropionate ointment, estradiol tablets, atovaquone and pr...

Strides Pharma Science Limited STAR Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 12102018] Prices from USD $250

SummaryStrides Pharma Science Limited Strides Pharma, formerly Strides Shasun Ltd, is a pharmaceutical company which offers generic products. It focuses on the development and manufacture of intellectual property led niche pharmaceutical products, overthecounter drugs and nutraceuticals. The company manufactures drugs in various oral dosage forms which include general tablets, hard gelatin capsule...


University of Chicago Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 12102018] Prices from USD $250

SummaryUniversity of Chicago UOC is an academic and research university that offers education and research in various disciplines. The university offers undergraduate, master's and PhD programs in the areas of anthropology, art history, astronomy and astrophysics, biochemistry and molecular biology, biophysical sciences, business, cancer biology, chemistry, classics, comparative human development,...

X4 Pharmaceuticals Presents Clinical Data Showing Combination of X4P-001 and Opdivo® (nivolumab) Improved Clinical Responses in RCC Patients Unresponsive to Opdivo Monotherapy

Findings with combination therapy of anti-PD-1 and CXCR4 antagonist in patients with clear cell renal cell carcinoma (ccRCC) presented in Poster Discussion session at ESMO 2018 X4 Pharmaceuticals, a clinical stage biotechnology company developing novel CXCR4 antago

ArQule Presents Orphan Disease Clinical Data at the American Society of Human Genetics (ASHG) 2018 Annual Meeting for Its pan-AKT Inhibitor, Miransertib (ARQ 092)

Three poster presentations confirm miransertib’s potential for treating patients with Proteus syndrome and PROS (PIK3CA-Related Overgrowth Spectrum) ArQule, Inc. (Nasdaq:ARQL) today announced the presentation of preliminary clinical data on miransertib (ARQ 092) in three poster presentations at the American Society of Human Genetics (ASHG) 2018 ...

Neuralstem Inc CUR Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 12102018] Prices from USD $250

SummaryNeuralstem Inc Neuralstem is a biopharmaceutical company that develops novel treatments for nervous system diseases. The company offers cell therapy treatment for ALS, ischemic stroke, spinal cord injury, multiple sclerosis, optic neuritis, Alzheimer's disease, traumatic brain injury, peripheral nerve injury, diabetic neuropathy, lysosomal disease, Parkinson's disease, huntington's disease ...

Outset Medical, Inc. Medical Equipment Deals and Alliances Profile [Report Updated: 12092018] Prices from USD $250

SummaryOutset Medical, Inc., Outset Medical is a medical technology company engaged in developing hemodialysis system for the treatment of kidney diseases. The company offers Tablo Hemodialysis machine that makes water clean, produces dialysate, takes blood pressure, and delivers medication for patients. Its touch screen display provides step by step pictures and instructions by reducing time inv...

Advanced Integrated Manufacturing Corp Ltd AXH Financial and Strategic SWOT Analysis Review [Report Updated: 28092018] Prices from USD $300

SummaryAdvanced Integrated Manufacturing Corp Ltd Aimcorp is an electronics manufacturing service provider that offers ecritical solutions. The company provides printed circuit boards and related assemblies for flight control and safety systems, aircraft cockpit instrumentations, navigation and communications; medical analytical instruments, and atomic absorption spectrometers. It offers mechanica...

NIH releases plan for determining whether sick research chimps should be moved to sanctuaries

MSD's Keytruda with Pfizer's Inlyta beats Sutent in most common kidney cancer

MSD has unveiled new Phase 3 data on its blockbuster anti-PD-1 cancer therapy Keytruda (pembrolizumab) as part of a combination, this time with Pfizer’s tyrosine kinase inhibitor Inlyta (axitinib) as a first-line treatment for the most common kidney cancer, advanced or metastatic renal cell carcinoma (RCC), showing that the combo met both its primary endpoints. The data revealed, according to an...

Clovis Oncology Presents Initial Results from the Ongoing Rubraca® (rucaparib) TRITON Program in Metastatic Castration Resistant Prostate Cancer (mCRPC) at ESMO 2018 Congress

44% confirmed objective response rate (ORR) reported in 25 RECIST-evaluable patients with a BRCA1/2 alteration in initial data from ongoing TRITON2 Phase 2 study; median duration of response has not yet been reached 51% confirmed PSA response rate shown in 45 PSA-evaluable patients with a BRCA1/2 alteration ...

STAT Plus: Clovis, with new study data, hopes to be first to develop a PARP for prostate cancer

Women with certain types of ovarian and breast cancers are benefiting from a relatively new class of drugs. Soon, men with advanced prostate cancer might be helped, too.

GRAIL to Present New Data from the Circulating Cell-free Genome Atlas (CCGA) Study at the European Society for Medical Oncology (ESMO) 2018 Congress

GRAIL, Inc., a healthcare company focused on the early detection of cancer, today announced that new data from the Circulating Cell-free Genome Atlas (CCGA) study will be presented by Minetta Liu, MD, Research Chair and Professor, Department of Oncology, Mayo Clinic, in an oral presentation at the European Society for Medical Oncology (ESMO) 2018 Congress ...

Cancer Research UK Manchester Institute enhances toolkit for computational and medicinal chemists with Flare for structure-based drug design

Cambridge, UK – 18th October 2018 – Cresset, innovative provider of software and contract research services for small molecule discovery and design, is pleased to announce that Cancer Research UK Manchester Institute (CRUK MI), has licensed Flare for fresh insights into structure-based drug design.“Putting easy-to use and visually driven structure-based design software in the hands of our me...

NetScientific (NSCI) - Steady as she goes

Edison Investment Research - Pharmaceutical & healthcare - NetScientific: NetScientific recently announced half-year results for 2018, with incremental progress continuing to be made, although we are yet to see that progress in reported revenues. In May 2018, Wanda, which focuses on digital health, and its partner Health Resource Solutions (HRS), achieved a 46% reduction in hospital readmissions i...

Global Ultrashort Wave Diathermy Machines Market Status and Outlook 20182025 [Report Updated: 12082018] Prices from USD $4000

Report SnapshotKey Content of Chapters Including and can be customized, report is a semifinished version, and it takes 4872 hours to upgradePart 1:Terminology Definition, Industry Chain,Industry Dynamics Regulations and Global Market OverviewPart 2:Upstream Raw Materials / Components Manufacturing Procurement Methods Channels and Cost , Major Regional Production Overview and Trade FlowPart 3:Pr...

Singlera Genomics and Fudan University unveil results showing Pan-Cancer Early Detection in the Taizhou Longitudinal Study

SAN DIEGO and SHANGHAI, Oct. 19, 2018 /PRNewswire/ -- Fudan University's Taizhou Health Science Institute and Singlera Genomics, a UC San Diego spinout company focused on non-invasive early cancer detection, today announce initial results from the Taizhou Longitudinal Study (TLS) during the 2018 American Society of Human Genetics (ASHG) Annual Meeting.  An oral pre...

Singlera Genomics unveils results of ColonES study demonstrating detection of advanced adenoma and colorectal cancer

SAN DIEGO and SHANGHAI, Oct. 19, 2018 /PRNewswire/ -- In collaboration with Fudan University Shanghai Cancer Center and Nanfang Hospital of Southern Medical University, Singlera Genomics, a UC San Diego spinout company focused on non-invasive cancer detection, presented the results of its initial ColonES retrospective study at the 2018 American Society of Human Genetics...

HORIBA Celebrates 50 Years of Innovation in Raman Spectroscopy

Discover the LabRAM Odyssey™ Anniversary Special Edition, fully loaded with our most popular innovations: Duoscan, ULF, SWIFT XS EMCCD, at an amazing price! Special 50 years anniversary series: true confocal Raman microscope enabling the most detailed images and analyses to be obtained with speed and confidence. Ideally suited for both micro and macro measurements, it offers advanced co...

Precision Temperature Control for NMR, EPR & XRD Studies

The AirJet XR Sample Cooler from SP Scientific is designed to provide precision sample temperature control (-90°C to +100°C) for NMR, EPR and X-Ray Diffraction instruments using a mechanically refrigerated, temperature-controlled air stream. Unlike some systems that use expensive, expendable cryogens such as liquid nitrogen or carbon dioxide to control temperature, the AirJet XR requi...

OncoSil Medical Ltd OSL Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 24092018] Prices from USD $250

SummaryOncoSil Medical Ltd OncoSil, formerly NeuroDiscovery Ltd is a medical device company that develops and commercializes treatments for patients with pancreatic and liver cancer. The company's lead product include oncosil, a brachytherapy device that emits beta radiation and is implanted directly inside the cancerous tumor during an endoscopic ultrasound guidance procedure. It offers various t...

Acura Pharmaceuticals Inc ACUR Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 27092018] Prices from USD $250

SummaryAcura Pharmaceuticals Inc Acura is a specialty pharmaceutical company that researches, develops, and commercializes tamperresistant products to prevent the abuse and misuse of medication. The company's proprietary technologies, Aversion, Limitx and Impede, are used to prevent product tampering associated with opioid abuse. Its Impede technology helps minimize the extraction and conversion o...

Aesculap Inc Product Pipeline Analysis, 2018 Update [Report Updated: 12092018] Prices from USD $750

SummaryAesculap Inc Aesculap is a medical device company that offers medical implants, surgical implants, and other related devices. The company's products comprise neurosurgery products, power systems, sterile processing products, surgical instruments, and wound closure products. It offers services such as sterile processing, surgical instrument and equipment repair services, payperuse programs, ...

NICE rejects Elil Lilly's Verzenio for breast cancer in draft guidance

Eli Lilly and patients with breast cancer patients in the UK have been dealt a blow as NICE confirmed that it has decided not to recommend the drugmaker’s therapy Verzenio (abemaciclib) for use on the NHS. The organisation’s draft guidance judged that the drug demonstrated efficacy on par with Pfizer’s Ibrance (palbociclib) and Novartis’ Kisqali (ribociclib) as a treatment for hormone rece...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks